NCT04737265View on ClinicalTrials.gov

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions

CardiotoxicityToxicity Due to ChemotherapyBreast CancerLymphomaCardiomyopathiesHeart Failure

Interventions

OTHER

Biomarker Guided Intervention

NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.

Trial Locations (3)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

19380

Chester County Hospital, West Chester

91010

City of Hope, Duarte

All Listed Sponsors

lead

Abramson Cancer Center at Penn Medicine

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT04737265 - Pilot Study of an NTproBNP Guided Strategy of Cardioprotection | Biotech Hunter | Biotech Hunter